A Phase 2 interventional study of GTx-024 and Matching Placebo in Stress Urinary Incontinence, sponsored by GTx. Withdrawn at 46 sites in United States. Open to female participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-09-14.
Sponsored by GTx · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 189 studies in Urinary Incontinence, Stress with a site in United States — 27 open to participants now, 40 under way, 3 of them phase 3. Urinary Incontinence, Stress · United States.
Among the 189 studies in Urinary Incontinence, Stress with a site in United States, this one is the 157th largest by enrollment of the 163 interventional ones that give a count, is one of 10 that started in 2018, is one of 12 in phase 2, and was the 101st registered.
653 studies on the registry are indexed under Urinary Incontinence, Stress; 121 are open to participants now.
Browse Urinary Incontinence, Stress studies →27 of the 189 studies in Urinary Incontinence, Stress with a site in United States are open now. Recruiting first, the newest first:
University of Miami · Sites in United States
Ages 18+ · Women only
Mayo Clinic · Sites in United States
Ages 18+ · Women only · Healthy volunteers
Eli Lilly and Company · Sites in United States, Canada, China and 6 more countries
Ages 18+ · Women only
Ohio State University · Sites in United States
Ages 18–50 · Women only
University of Rochester · Sites in United States
Ages 18+ · Men only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 74 Urinary Incontinence, Stress studies recruiting now, 42 (57%) set no upper age limit and 18 (24%) stop at 75 or younger; 2 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 80 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
189 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 18 · Phase 3 23 · Phase 4 15
First in 2001; this study’s year is marked. 10 started in 2018.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 98 across the 163 interventional studies, 98 across the 26 observational. Of the 129 that completed or were terminated, 56 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
72 of 189 have an industry lead sponsor. The 10 most frequent:
GTx is the lead sponsor of 19 studies on the registry; none are open to participants now.
GTx has 4 studies filed under Urinary Incontinence, Stress — fewer than ten, so there is no comparison to draw.
9 of the studies in Urinary Incontinence, Stress with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06968741UroMems SASA Study to Assess the Safety and Effectiveness of the UrOActive® Artificial Urinary sPHincter (AUS) | 2026-12 |
| NCT06111209Brigham and Women's HospitalThe Anabolic Effect of Testosterone on Pelvic Floor Muscles | 2026-12-31 |
| NCT06369922University of RochesterTENS Analgesia During Outpatient Urethral Bulking for Stress Urinary Incontinence. | 2027-01-31 |
| NCT06706362Ohio State UniversityAssessing the Utility of Prophylactic Antibiotics at Time of Urethral Bulking Using Bulkamid (Bulkamid Study) | 2027-04-15 |
| NCT07008898University of Alabama at BirminghamSequence of Midurethral Sling Placement During Robotic Sacrocolpopexy | 2027-05 |
Add all 9 to your calendar (.ics) → With an account.
Among the 189 studies in Urinary Incontinence, Stress with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study will enroll only from the first 225 subjects who were randomly assigned to treatment in G201002 (irrespective of the treatment allocation, i.e., GTx-024 or placebo) and who have completed the 12-week treatment period and 16-week durability period to assess the long-term durability of response to GTx-024 on SUI symptoms. The extension study will follow subjects for an additional 20 weeks to help better assess the durability of response in these subjects and will provide additional efficacy and safety data for the subjects. Subjects will not be provided with any study treatments and will be off-drug during this extension study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects previously enrolled in the placebo arm of study G201002.
Drug: Matching Placebo
Subjects previously enrolled in the 1 mg GTx-024 arm of study G201002.
Drug: GTx-024
Subjects previously enrolled in the 3 mg GTx-024 arm of study G201002.
Drug: GTx-024
Subjects will not be provided with any study treatments and will be off-drug during this extension study. Intervention was administered during study G201002.
Also known as: enobosarm
Subjects will not be provided with any study treatments and will be off-drug during this extension study. Intervention was administered during study G201002.
Durability of Response, stress incontinence
Change from G201002 baseline in the mean number of stress incontinence episodes per day
Time frame: baseline to 20 weeks
Durability of Response, patient global impression of severity
Change from G201002 baseline in patient global impression of severity scale (PGI-S; scale: 1-normal, 2-mild, 3-moderate, 4-severe; representing severity of urinary tract dysfunction)
Time frame: baseline to 20 weeks
Durability of Response, patient global impression of improvement
Change from G201002 baseline in patient global impression of improvement scale (PGI-I; scale: 1-very much better, 2-much better, 3-a little better, 4-no change, 5-a little worse, 6-much worse, 7-very much worse; representing change in urinary tract dysfunction from initiation of therapy)
Time frame: baseline to 20 weeks
Durability of Response, urge incontinence
Change from G201002 baseline in the mean number of urge incontinence episodes per day
Time frame: baseline to 20 weeks
Durability of Response, total incontinence
Change from G201002 baseline in the mean number of total (stress + urge) incontinence episodes per day
Time frame: baseline to 20 weeks
Plan to share: No
Ran from May 2018 to primary completion in Sep 2018, 3 months.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ostarine
Urinary Incontinence, Stress →
GTx